Deep learning in drug discovery and diagnostics market analysis (2026–2030)
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Is The Market Size Of The Deep Learning In Drug Discovery And Diagnostics Market Expected To Change From 2026 To 2030?
The deep learning in drug discovery and diagnostics market size has experienced substantial expansion in recent years. It is forecast to grow from $10.58 billion in 2025 to $13.61 billion in 2026, achieving a compound annual growth rate (CAGR) of 28.7%. The historical increase in size can be credited to the greater accessibility of extensive biomedical datasets, enhanced computational capabilities for training models, the broadening adoption of AI in pharmaceutical R&D, a rising need for accelerated drug discovery cycles, and the early achievements of deep learning diagnostic models.
The market for deep learning in drug discovery and diagnostics is poised for substantial expansion over the next few years. It is projected to climb to $36.96 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 28.4%. This growth during the forecast period is fueled by escalating investments in AI-based healthcare solutions, a surging demand for precision medicine, the broadened adoption of AI across clinical workflows, the increasing utilization of real-world evidence data, and growing regulatory acceptance of AI-assisted diagnostics. Prominent trends anticipated in this period include the rising implementation of deep neural networks in drug screening, an increased application of AI-driven predictive modeling in diagnostics, deeper integration of multi-omics data analysis, the expansion of automated clinical decision support systems, and a heightened focus on personalized medicine platforms.
Access Your Free Sample Report For In-Depth Market Analysis:
What Factors Are Contributing To The Growth Of The Deep Learning In Drug Discovery And Diagnostics Market?
The increasing demand for personalized medicine is projected to fuel the expansion of the deep learning in drug discovery and diagnostics market moving forward. Personalized medicine customizes medical treatments and interventions to an individual’s genetic, environmental, and lifestyle factors, with the goal of optimizing efficacy and minimizing side effects. The rising demand for personalized medicine is spurred by advancements in genomics and data analytics, which enable more precise and effective treatments based on individual patient profiles. Deep learning in drug discovery and diagnostics enhances personalized medicine by analyzing complex biological data to identify unique biomarkers and predict patient responses to treatments with greater accuracy. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to six in 2022. Therefore, the growing demand for personalized medicine drives the deep learning in drug discovery and diagnostics market.
Which Segments Define The Deep Learning In Drug Discovery And Diagnostics Market Segment Structure?
The deep learning in drug discovery and diagnostics market covered in this report is segmented –
1) By Type: Drug Discovery, Diagnostics, Forensic Interventions, Other Types
2) By Drug Type: Small Molecule Drugs, Biologics Drugs
3) By End Use Industry: Pharmaceutical Companies, Biotechnology Companies, Contract Research Organizations (CROs), Healthcare Information Technology (IT)
Subsegments:
1) By Drug Discovery: Target Identification, Drug Screening, Lead Optimization, Predictive Modeling
2) By Diagnostics: Medical Imaging Analysis, Genomic Data Interpretation, Disease Detection Algorithms, Personalized Medicine
3) By Forensic Interventions: Digital Pathology, Forensic DNA Analysis, Toxicology Screening, Crime Scene Reconstruction
4) By Other Types: Biomarker Discovery, Predictive Analytics in Healthcare, Patient Data Management Systems
What Trends Are Shaping The Future Of The Deep Learning In Drug Discovery And Diagnostics Market?
Leading companies operating in the deep learning in drug discovery and diagnostics market are integrating sophisticated technologies, such as generative artificial intelligence (AI) and machine-learning (ML)–driven automation platforms, to boost operational efficiency, reduce research and development (R&D) expenditures, and expedite early-stage therapeutic discovery. These generative AI and ML-driven automation platforms are computational systems that learn from chemical and biological data to virtually design new drug candidates, predict molecular behavior, and automatically synthesize and test compounds using robotic systems, thereby lessening reliance on traditional high-throughput screening. For example, in July 2024, Exscientia, a UK-based AI-driven drug-design company, unveiled its AWS-powered AI/ML platform. This platform integrates a “DesignStudio” for AI-based molecule generation with an “AutomationStudio” for robotic lab synthesis and testing. The system functions in a closed “design–make–test–learn” loop, where experimental data continuously refines the AI models, substantially accelerating discovery, enhancing scalability, and enabling the more precise and cost-effective development of novel therapeutics.
Who Are The Established Players Within The Deep Learning In Drug Discovery And Diagnostics Market?
Major companies operating in the deep learning in drug discovery and diagnostics market are Google Inc., Microsoft Corporation, International Business Machines Corporation, NVIDIA Corporation, Zebra Medical Vision Ltd, Tempus Labs Inc., Nanostring Technologies Inc., Owkin Inc., Insilico Medicine Inc., SOPHiA GENETICS SA, Qureai Technologies Pvt Ltd, H2Oai Inc., Arterys Inc., Deep Genomics Inc., GNS Healthcare Inc., MedAware Systems Inc., PathAI Inc., Kheiron Medical Technologies Ltd, CureMetrix Inc., OncoImmunity AS, Proscia Inc., BenevolentAI Ltd, BioXcel Therapeutics Inc.
Get The Full Deep Learning In Drug Discovery And Diagnostics Market Report:
Which Region Is The Leading Market For The Deep Learning In Drug Discovery And Diagnostics Market?
North America was the largest region in the deep learning in drug discovery and diagnostics market in 2025. The regions covered in the deep learning in drug discovery and diagnostics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Deep Learning In Drug Discovery And Diagnostics Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Deep Learning In Drug Discovery And Diagnostics Market 2026, By The Business Research Company
Drug Discovery Services Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-discovery-services-global-market-report
Artificial Intelligence In Drug Discovery Market Report 2026
Drug Discovery Market Report 2026
https://www.thebusinessresearchcompany.com/report/drug-discovery-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
